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Abstract
Background: Dependence receptors have been proved to act as tumor suppressors in tumorigenesis. Neogenin, a DCC
homologue, well known for its fundamental role in axon guidance and cellular differentiation, is also a dependence receptor
functioning to control apoptosis. However, loss of neogenin has been reported in several kinds of cancers, but its role in
glioma remains to be further investigated.
Methodology/Principal Findings: Western blot analysis showed that neogenin level was lower in glioma tissues than in
their matching surrounding non-neoplastic tissues (n=13, p,0.01). By immunohistochemical analysis of 69 primary and 16
paired initial and recurrent glioma sections, we found that the loss of neogenin did not only correlate negatively with
glioma malignancy (n=69, p,0.01), but also glioma recurrence (n=16, p,0.05). Kaplan-Meier plot and Cox proportional
hazards modelling showed that over-expressive neogenin could prolong the tumor latency (n=69, p,0.001, 1187.66162.6
days versus 687.46254.2 days) and restrain high-grade glioma development (n=69, p,0.01, HR: 0.264, 95% CI: 0.102 to
0.687). By Methylation specific polymerase chain reaction (MSP), we reported that neogenin promoter was methylated in
31.0% (9/29) gliomas, but absent in 3 kinds of glioma cell lines. Interestingly, the prevalence of methylation in high-grade
gliomas was higher than low-grade gliomas and non-neoplastic brain tissues (n=33, p,0.05) and overall methylation rate
increased as glioma malignancy advanced. Furthermore, when cells were over-expressed by neogenin, the apoptotic rate in
SHG-44 was increased to 39.7% compared with 8.1% in the blank control (p,0.01) and 9.3% in the negative control
(p,0.01).
Conclusions/Significance: These observations recapitulated the proposed role of neogenin as a tumor suppressor in
gliomas and we suggest its down-regulation owing to promoter methylation is a selective advantage for glioma genesis,
progression and recurrence. Furthermore, the induction of apoptosis in SHG-44 cells after overexpression of neogenin,
indicated that neogenin could be a novel target for glioma therapy.
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Introduction
Gliomas are the commonest primary tumors in central nervous
system (CNS) arising from neuroepithelial cells and they account
for over 50% of primary brain tumors. Recent epidemiological
reports showed that the incidence of gliomas was about 6.5/
100,000 and the mortality was about 4.3/100,000 per year and
the 5-year survival rate was only 33.4% [1,2]. In clinical
pathological classification, gliomas are categorised as astrocytoma,
oligodendroglioma, oligoastrocytoma, glioblastoma among others.
Depending on pathological characteristics of tumor, gliomas are
divided into four grades: I, II, III and IV in ascending order of
malignancy. Generally, grade I and II are considered as low-grade
gliomas while grade III and IV are high-grade gliomas [3]. The
pattern for growth of high-grade glioma is infiltrating and dilative,
with the invasion and destruction of surrounding tissues. So far,
surgery is the main therapeutic regimen but microscopic
glioblastoma, also described as Grade IV glioma, often infiltrates
much larger areas than is seen on Magnetic Resonance Imaging
(MRI) or Computed Tomography (CT), and as such surgical
treatment is at best insufficient, consequently post-operative
recurrence is frequently encountered accompanied by short
survival time of approximately 14 months [4]. Globally, developed
countries registered a higher mortality rate than developing
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that ionising radiation, chemical and genetic susceptibility are
main etiologic factors in glioma formation [4]. However,
molecular mechanism for glioma progression and recurrence is
still not precisely understood. There is anticipation that integration
of genetic and/or molecular information would not only assist
pathologists in differentiating glioma grades and disease progres-
sion rate, but also uncover molecular markers that could aid in
diagnosis and prognosis.
Neogenin, a homologue of Deleted in Colorectal Cancer (DCC),
is widely distributed in the CNS [6–8] as a dependent receptor of
repulsive guidance molecule a (RGMa). It was first identified after
separation from chicken embryo where it was reported to regulate
end stage of cellular differentiation [9]. Subsequent studies revealed
its roles in cell migration and development, apoptosis, histogenesis,
angiogenesis and epithelial cell renewal [10–14]. It belongs to
immunoglobulin super family consisting of four immune globulins
followed by six fibronectin type III domains in the extracellular
region, a transmembrane region and a cytoplasmic region endowed
withdeathdomain[15].Itisreportedthatalterationofexpressionin
thedependent receptorssuchasDCC,UNC5H,neogenin[16]and
their ligands, netrin-1 [17] and RGMa [18,19] would cause loss of
pro-apoptotic activity and even lead to tumorigenesis [20–22]. In
recent years, dependent receptors have been identified as potential
cancer inhibitors in various cancers [23–25]. Gain of netrin-1 and/
orlossofDCCwouldaccelerategliomaprogression[26–29].Down-
regulation of neogenin has been reported in primary breast cancer
and metastatic breast cancer relative to the normal breast tissues
[30]. Berrar and colleagues demonstrated that in lung cancer
patients, shorter survival time was exhibited in those with lower
expression of neogenin compared with their counterparts with
higher expression [31]. Though neogenin is widely distributed in
CNS, its role in gliomas remains to be elucidated. In this study we
probed the correlation by immunological, promoter methylation
and flow cytometry techniques.
Results
Lower Expression of Neogenin in Gliomas than
Surrounding Areas
In this study, a clear pattern of neogenin expression in gliomas
was the first priority. Two normal brain tissues and thirteen paired
surrounding and glioma tissues (Table S1) were analysed (each
glioma tissue was paired with its neighbouring non-neoplastic
tissue). Immunohistochemistry results showed that cells in the
surrounding tissues were sparse, well distributed, rarely polynu-
clear and karyokinetic, normal glial cell shape though seldom
hyperplasia (Fig. 1A), whereas in the typical tumor tissues, cells
were more heterogenous: ranging from small to giant, disordered,
polynuclear to karyokinetic (Fig. 1B). Western blot analysis showed
that neogenin in tumor tissues was lower relative to that in the
normal brain tissues and surrounding non-neoplastic tissues, using
b-actin as an internal control for electrophoresis efficiency (paired
t-test, n=13, p,0.01, Fig. 1C, D). Strikingly, the down-expression
of neogenin was more clear in high-grade gliomas (n=7) and
female patients (n=7) than low-grade gliomas and male patients
(Table 1, paired t-test, n=7, p,0.01). These results signified that
the expression of neogenin was down-regulated in gliomas and
more pronounced in high-grade gliomas.
Negative Relationship between the Expression of
Neogenin and Glioma Malignancy
Since there was loss of neogenin in glioma tissues compared to
their surrounding non-neoplastic tissues, sixty nine primary glioma
cases (Table S2) from January, 2006 to January, 2011 in the
Pathological Specimen Library of the First Clinical Hospital of
Jilin University were collected for examination of relationship
between neogenin expression and glioma malignancy. All sections
were diagnosed as gliomas according to pathological characteris-
tics and classified into grade I-IV: including grade I (n=6), grade
II (n=28), grade III (n=14) and IV (n=21) respectively (Table 2).
The results from immunohistochemical assay showed that
expression of neogenin was decreased, which was associated with
grade advancement (Fig. 2A–D and A’–D’). The average integral
optical density (IOD) of positive signal representing the relative
neogenin level was significantly different between grade I and III,
grade I and IV, grade II and III, and grade II and IV (One-Way
ANOVA, n=69, p,0.01, Fig. 2E), and also was distinct between
the low-grade and the high-grade gliomas (independent t-test,
n=69, p,0.05, Fig. 2F, Table 2). These results indicated that
down-regulation of neogenin was negatively correlated with the
grade advancement which meant that malignancy of gliomas was
promoted.
Down-regulation of Neogenin Expression Accelerated
the Progress of Gliomas
Then, we wondered whether the expression level of neogenin
was also correlated with clinical characteristics of gliomas. The
clinical features of 69 primary patients used above were analysed,
including tumor latency (the period from the first symptom to
diagnosis [32,33]), age, gender, tumor size and location (Table 2
and Table S2). Remarkably, neogenin expression was lower in
acute latency group, indicating that its loss may accelerate glioma
progress (Fig. 3A, independent t-test, n=69, p,0.05). However,
there was no statistical difference of neogenin expression between
tumor location, gender, length of being in hospital, age and tumor
size (Fig. 3B–F).
Furthermore, Kaplan-Meier curve and Cox proportional
hazards modelling were used to identify the potential relationship
between neogenin and high-grade gliomas. The high-grade
gliomas were defined as the Failure event. The patients (n=69)
were divided into two groups by Median, the middle number of
IOD in the list (Table S2). The Kaplan-Meier plot showed that the
patients with overexpression of neogenin had more low-grade
glioma rate (71.4% versus 26.5%) and longer tumor latency
(1187.66162.6 days versus 687.46254.2 days) (n=69, p,0.001,
Fig. 4). Multivariable analysis demonstrated that neogenin could
be a beneficial factor to restrain low-grade gliomas from
progressing into higher more aggressive grades that are renowned
for poor clinical outcome (n=69, p,0.01, Hazard Ratio 0.264,
95% Confidence Interval: 0.102 to 0.687, Table 3).
Down-regulation of Neogenin Accelerated the
Recurrence of Gliomas
In order to examine the association between neogenin and
glioma recurrence, paired primary and recurrent sections (n=16,
Table S3) were collected from 16 patients, who were diagnosed as
gliomas during January 2001 to January 2011. The result showed
that mean expression of neogenin in primary tissues was
significantly higher than the recurrent ones (Fig. 5A–C, Table 4
and Table S3, paired t -test, n=16, p,0.05). Interestingly, the
down-regulation in low-grade gliomas (n=5, p,0.05) and male
patients (n=11, p,0.05) was more significant than high-grade
gliomas and female patients in the recurrent cases (Table 4). These
results may offer a clue that progressive down-regulation of
neogenin could be one of the factors behind glioma reappearance
after resection.
Correlation between Neogenin and Glioma
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Accumulating evidences indicate that cancer is the result of
various genetic and epigenetic alterations of tumor suppressor
genes [34]. It has been reported in gliomas, isocitrate dehydro-
genase mutation 1 (IDH1) is associated with DNA methylation
phenotype [35]. Furthermore, data from microarray studies also
showed existence of a glioma-CpG Island methylator phenotype
(G-CIMP) that was used to define a distinct subgroup of glioma
[36]. The profile of somatic epigenetic as well as genetic alteration
is central to understand the pattern of disrupted cellular function
responsible for deadly behaviour of gliomas. We selected
methylation as an epigenetic marker which has been established
in most cancers as one of the reasons responsible for gene
deregulation. By analysing the sequence of neogenin promoter, we
found that there were two CpG islands prone to methylation.
Subsequent methylation-specific polymerase chain reaction (MSP)
on the neogenin promoter validated the presence of epigenetic
alteration in glioma. In agreement with our hypothesis, 31.0% of
gliomas (9/29) were methylated, while no methylation was
observed in the non-neoplastic brain tissues (0/4) and cell lines
U87MG, U251MG and SHG-44 (0/3). Intriguingly, it was
observed that 12.5% (1/8) of grade II, all of grade III (2/2) and
35.3% (6/17) of grade IV glioma were methylated but no
methylation in grade I (0/2). Combining above data, 42.1% (8/19)
of high-grade gliomas presented methylation of neogenin promot-
er, compared with 10% (1/10) of low-grade gliomas. Classified
statistic showed that the methylation in high-grade gliomas was
more frequent than low-grade gliomas and non-neoplastic brain
tissues (Fig. 6, Table 5, Chi-square test, n=33, p,0.05), indicating
Figure 1. The difference of neogenin expression between gliomas and their homologous surrounding tissues. (A–B) Representative
immunohistochemical pictures (2006magnification): (A) The surrounding tissue of the tumor, the arrow points to a positive normal cell; (B) The
typical glioblastoma area, the arrow points to positive tumor cell. (C) Western blot showed neogenin expression in normal brains (N), surrounding
non-neoplastic tissues (S) and homologous gliomas (T). (D) Statistical graph of neogenin expression in surrounding non-neoplastic tissues and
gliomas. Paired t -test, n=13, ** p,0.01, error bars indicate standard error means.
doi:10.1371/journal.pone.0038074.g001
Table 1. Clinicopathologic features and relative neogenin
level profile in 13 paired surrounding and glioma tissues
(January – November, 2011).
Ratio of neogenin/b-actin
(Mean±SD)
Feature Variable No.(%) Surrounding Tumor p-value
*
Gender Female 7(53.8) 0.73460.426 0.11060.208 0.005
Male 6(46.2) 1.15961.126 0.49860.550 0.079
Histology Low-grade 6(46.2) 0.68860.484 0.29060.339 0.336
High-grade 7(53.8) 1.13761.015 0.28860.530 0.004
Total Glioma 13(100) 0.93060.817 0.28960.434 0.001
SD: standard deviation;
*: paired t-test.
doi:10.1371/journal.pone.0038074.t001
Correlation between Neogenin and Glioma
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grade.
Induction of Apoptosis after Neogenin Overexpression in
SHG-44 Cell Line
Then, to further understand the role of neogenin in glioma, it
was over-expressed in cell line SHG-44 by transfection. Cells were
harvested at 48 hours and analysed by Western blot for
verification of neogenin expression (Fig. 7A). During the cell
culture, we found that cells with over-expressive neogenin
dissociated from each other unlike in blank and negative control,
in which cells grew in cohesion (Fig. 7B–D). In addition, flow
cytometry assay showed that 39.7% of cells transfected with
neogenin underwent apoptosis compared to 8.1% in the blank
control (p,0.01) and 9.3% in the negative control, which were not
transfected and transfected with empty vector respectively
(p,0.01, Fig. 7E and F). These observations further indicated
that neogenin was a glioma suppressor by inducing apoptosis in
SHG-44 cells.
Discussion
Contrary to the observations made by Meyerhardt and co-
workers in 1997 [37], where they reported that neogenin was
unaffected in a range of cancers including glioblastoma, the
conclusions from Hanninen et al showed that the neogenin mRNA
levels were lower in oligodendrogliomas, oligoastrocytomas,
medulloblastomas and astrocytomas than in normal brain regions
[38]. Moreover, down-regulation of neogenin expression was also
reported in colon cancers [39], prostate tumors [40] and breast
cancers [30]. Our results supported that neogenin expression in
the typical glioma areas was lower than in the matching
surrounding areas (n=13). In agreement with expression of other
dependent receptors like DCC and UNC5H which have been
regarded as tumor suppressors because of their reported loss of
function in variety of cancers and pro-apoptotic ability [41,42].
Taken together, neogenin is shown to play the role of tumor
suppressor in glioma.
The interesting finding in this study was that neogenin
expression was negatively related with glioma grade (n=69).
Down-regulation of neogenin expression could increase the degree
of malignancy. Importantly, in most of the recurrent cases,
neogenin expression was further reduced compared with the
matching primary tumors from the same patient especially in the
low-grade gliomas, indicating that progressive neogenin loss in
glioma might begin at early stage and promote its recurrence after
resection. As expected, the phenotype for loss of neogenin
expression could be similar to DCC, inactivation of which helped
to further glioma progression and glioblastoma regeneration
[27,43].
On the basis of clinical experiences, malignancy of glioma is
closely correlated with tumor latency, size, occasionally with
patient’s age among other factors. The patients with acute tumor
latency probably have higher risk of developing high-grade glioma.
By exploring the correlation between neogenin and glioma
latency, we found that expression of neogenin was lesser in
gliomas with acute latency, meaning that over-expressive patients
were with lower hazard ratio to advance to high-grade gliomas.
Epidemiological study suggests that males are more prone to
gliomas than females [2]. But depending on neogenin expression,
Figure 2. Immunohistochemical analysis of neogenin in primary gliomas. (A–D) Representative immunohistochemical pictures of grade I-IV
glioma respectively, (A’–D’) Magnification of the red squares in (A–D), (A–D) 2006magnification; (A’–D’) 4006magnification. (E) Scatter diagram of
neogenin expression in 69 primary gliomas, blue bars are the means of four grades, n=69, One-Way ANOVA was used in statistical analysis. (F)
Histogram of mean neogenin expression in low-grade gliomas and high-grade gliomas, statistical analysis was performed with independent t-test.
*p,0.05, **p,0.01, error bars indicate standard error means.
doi:10.1371/journal.pone.0038074.g002
Figure 3. The classified statistics of neogenin expression in 69 primary gliomas. (A–D) Histograms of mean neogenin levels in different
statistic groups: (A) tumor latency, (B) tumor location, (C) gender, (D) duration of being in hospital, (E) age, (F) tumor size. N, the number of cases in
different statistic groups, statistical methods were performed with independent t-test and One-Way ANOVA, *p,0.05, error bars indicate standard
error means.
doi:10.1371/journal.pone.0038074.g003
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males (n=6) in comparison of surrounding and primary gliomas
tissues, indicating that women patients may advance to high-grade
glioma faster than men patients during early stage of tumor
(Table 1, p,0.01). In contrast, while males (n=16, Table 5) had
higher frequency of promoter methylation, they underwent
remarkable down-regulation of neogenin (n=11, p,0.01) than
females (n=5, p.0.05) in recurrent gliomas (Table 4) implying
that men patients may recur easily and progress faster in later stage
of glioma. In most cases, larger tumors have worse pathological
behaviour. Conformably, our data also showed that neogenin
expression was negatively related to glioma size though this was
not statistically significant. Meanwhile, the lowest neogenin level
was detected in old aged patients who have been thought to
experience a poor prognosis [5]. The average neogenin expression
in the supratentorial cases was significantly lower than in
subtentorial. Thus, it might mean that the malignancy of
supratentorial group was more serious than subtentorial. In
premise of increasing samples, the significant differences among
glioma size, location and patient’s age might be clear.
Summarizing above, we suppose down-regulation of neogenin
expression in gliomas is an important factor for glioma genesis,
time to progression and recurrence. Survival time of the patients
with lower neogenin might be shortened [31]. Thus neogenin may
act a molecular marker for prognosis.
Promoter methylation is probably one of the reasons recognised
to repress tumour suppressor genes in malignancy [34]. Our
findings on neogenin methylation were in harmony with other
dependent receptors such as DCC and UNC5H, where their loss
of expression in several cancers was due to promoter methylation
[44,45]. In this study, the ratio of neogenin methylation increased
with glioma grade possibly suggesting a strong positive correlation
between promoter methylation and inactivation of neogenin.
Considering that, we speculate promoter methylation to be one of
the reasons for inactivation of neogenin expression in gliomas,
high-grade gliomas in particular, resulting in insufficiency of
neogenin at the cell membrane hence alter physiological functions
working to the advantage of glioma genesis and/or progression.
The observed methylation in gliomas reminisces the reports of
existence of G-CIMP which was tightly associated with IDH1
mutation and exhibited better prognosis [35,36]. Our observations
in current study indicated neogenin did not belong to G-CIMP
loci because of strong anti-correlation between neogenin methyl-
ation and G-CIMP-positive or IDH1 mutation status, similar to
transmembrane protein tomoregulin (TMEFF2) which was
hepermethylated and associated with worse prognosis [46].
Epigenetic alteration, however, cannot exactly explain all
phenomena in our study. Perhaps other mechanisms like loss of
heterozygosity or gene mutations which have been reported in
DCC and Unc5H [47–49] could further provide more evidence to
elaborate neogenin’s role in gliomas.
How does the deficiency of neogenin lead to tumorigenesis? The
current view is that asymmetry of dependent receptors and their
ligands would not only interrupt cell migration and differentiation
but also actively inhibit the pro-apoptotic signalling [50]. Firstly,
the ligands may be relatively surplus and free due to inactivation
and downregulation of dependent receptors [26,51]. Secondly, the
ligands could gain expression in the malignant tumors [52–54]. If
either or both of them happen, the surplus ligands would block
apoptotic signal because of the mismatching of ligands and
receptors [55,56], thus the atypical glial cell would be immortal-
ized to the advantage of tumorigenesis and perhaps accelerated.
The mechanism fits for elaborating the observed dysfunction of
neogenin in gliomas and induction of apoptosis in SHG-44 cell
line after overexpression of neogenin further supports it. Another
proposal is that lower neogenin expression could enhance
Figure 4. Kaplan-Meier survival curves for overall progression
to high-grade glioma. Failure event for computation of this curve
was diagnosed as the high-grade glioma. Higher neogenin patients are
marked in green color, lower neogenin patients are marked in blue
color.
doi:10.1371/journal.pone.0038074.g004
Table 3. Multivariate hazard ratios of progression to high-grade gliomas in 69 primary glioma patients (January, 2006 – January,
2011).
95.0% Confidence Interval
Factor p-value Hazard Ratio Lower Upper
Neogenin (Higher expression vs. Lower expression)
{ 0.006 0.264 0.102 0.687
Tumor size (Increase of 3 cm) 0.809 1.077 0.592 1.960
Gender (Males vs. Females) 0.439 1.424 0.582 3.489
Age (Increase of 30 years) 0.422 1.333 0.661 2.689
Multivariate hazard ratios and 95% Confidence Intervals were obtained by using Latency as time-scale and High-grade glioma as Failure event.
{: divided by Median of
neogenin IODs listed in the Table S2.
doi:10.1371/journal.pone.0038074.t003
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malignancy of glioma.
In summary, neogenin, one of the dependent receptors, is a
tumor suppressor in glioma. Its expression is negatively correlated
with glioma malignancy. And its loss even accelerates the process
of glioma and recurrence after resection attributing to dysfunction
of apoptosis. Methylated promoter of neogenin in gliomas may be
one of the reasons for the downregulation of neogenin expression,
indicating that adjustment of neogenin could be a strategy for
glioma therapy.
Materials and Methods
Cell Culture and Transfection
Human glioma cell lines U251MG, U87MG and SHG-44 were
obtained from the Cell Bank of Chinese Academy of Sciences
(Shanghai, China), and were cultured in Dulbecco’s Modified
Eagle Medium (DMEM), supplemented with 10% newborn calf
serum at 37uC in an atmosphere of 5% CO2. SHG-44 cells were
transiently transfected in 6-well plate with either human neogenin
cDNA or the empty vector pcDNA3.1 using Lipofectamine 2000
reagent (Invitrogen).
Glioma Tissue Samples
The fresh glioma tissues were obtained from the First Clinical
Hospital of Jilin University, frozen in liquid nitrogen immediately
after resection, including paired glioma and their surrounding
tissues for Western blot analysis of neogenin expression (Table S1,
n=15), graded glioma tissues for methylation assay (Table S4,
n=33). The formalin fixed paraffin-embedded primary glioma
sections (Table S2, n=69 ) and paired initial and recurrent glioma
samples (Table S3, n=16) were from the Pathlogical Samples
Library in the same hospital for immunohistochemical assay. All
the sections were diagnosed by two independent neuropathologists
to assign histological types and classified into 4 grades according to
the 2007 WHO classification of tumors of the central nervous
system. The fresh tissues were taken from the patients being in the
hospital from January to November 2011. The primary patients
who were in the hospital from January 2006 to January 2011 and
the recurrent patients from January 2001 to January 2011 were
treated with glioma resection only, without radiotherapy and
chemotherapy. The tissues for immunohistochemistry were
sectioned into 5 mm thick and re-checked by pathologists L. Q.
and D. W. Permissions for using these materials were obtained
from The Regional Ethical Review Board of Jilin University and
Northeast Normal University, Changchun, China and written
consents were obtained from all patients.
Immunohistochemistry
Immunohistochemical analysis was performed on paraffin-
embedded tissues sections. The antigen retrieval was performed
by boiling sections in 10 mM citrate buffer pH 6.0 at the
temperature of 100uC and the pressure of 0.12 MPa for 90 s.
The immunohistochemical ultrasensitive
TM S-P kit (Maixin
Biotechnology, Fuzhou, China) was used for immunohistochem-
istry of neogenin. The procedure was in accordance with the
instruction manual. Neogenin antibody was from Santa Cruz,
USA. Chromogen reaction was performed according to DAB kit
(Maixin Biotechnology, Fuzhou, China). At last, the sections were
stained again with haematoxylin. The immunohistochemical
sections were re-checked by independent pathologists L. Q. and
Y. W.
Western Blotting
The total protein of samples was extracted from normal brain
tissues, paired glioma tissues and surrounding tissues. Equal
amount of total protein from cell or tissue lysis in each lane was
electrophoresed in 8% SDS-PAGE, transferred to PVDF mem-
brane at the voltage of 70V for 2 hours. The goat anti-neogenin
antibody (Santa Cruz Biotechnology, California, USA) was diluted
as 1:1000 to hybridize the neogenin in samples. The horse-radish
Figure 5. Expression of neogenin in 16 paired primary and recurrent glioma sections. (A-B) Representative immunohistochemical pictures
(2006magnification): (A) primary glioma, (B) matching recurrent glioma. (C) statistical graph of mean neogenin expression in primary and recurrent
gliomas. Paired t-test, n=16, * p,0.05, error bars indicate standard error means.
doi:10.1371/journal.pone.0038074.g005
Table 4. Primary and recurrent clinicopathologic features of
16 patients (January, 2001 – January, 2011).
Feature Variable No.(%)
Primary
IOD
Recurrent
IOD p-value
*
Gender Female 5(31.3) 563167750 400264473 0.745
Male 11(68.8) 16905615683 421763552 0.015
Histology Low-grade 5(31.3) 1339767798 268762057 0.025
High-grade 9(56.3) 11387616083 482464626 0.226
Uncertain
{ 2(12.5) 22317625073 477261635 –
Total Glioma 16(100) 13381614461 414963709 0.018
IOD: integral optical density;
IOD values were supplied as Mean6Standard Deviation.
*: paired t-test;
{: undefined grade gliomas.
doi:10.1371/journal.pone.0038074.t004
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Missouri, USA) was used to recognise immunocomplexes which
were finally visualised by ECL Plus Western blotting system
(Amersham, Buckinghamshire, UK).
Methylation-specific Polymerase Chain Reaction
(MSP) [58]
EZ DNA Methylation- Direct
TM Kit (the Epigenetics Compa-
ny, California, USA) was used for methylation test. First genomic
DNAs were extracted from tissues or cell lines. Then these DNAs
were treated by bisulfite under the instruction manual. PCR
conditions were set up as follows: 95uC initial Taq-Gold activation
for 2 minutes, 95uC 30 seconds denaturation, 58uC 40 seconds
annealing, 72uC 30 seconds extension for 35 cycles, and a final
extension at 72uC for 5 minutes. The primer sequences were used
as follows: the forward methylated primer 59-CGCGTTAG-
GGTTTAGTAAGAGTC-39, the reverse methylated primer 59-
ATATAAAACCTCAAAAAAAACCGAA-39; the unmethylated
forward primer 59-TGTGTTAGGGTTTAGTAAGAGTTGG-
39, the unmethylated reverse primer 59-ATATAAAACCT-
CAAAAAAAACCAAA-39. Each MSP was repeated at least
3 times.
Flow Cytometry
Cells were transfected with either empty vector or neogenin
expression plasmid as previously described and harvested at 48 h.
Subsequently, cells were stained with annexin V-FITC and
propidium iodide for 15 min in dark. Flow cytometric analysis
was performed according to instruction manual of Annexin V-
Figure 6. Methylation of neogenin promoter in 3 kinds of glioma cell lines, 4 non-neoplastic brain tissues and 29 gliomas. L: ladder,
NB: non-neoplastic brain tissues, U: unmethylated, M: methylated, red asterisks indicate methylation.
doi:10.1371/journal.pone.0038074.g006
Table 5. Clinicopathologic features and the methylation of neogenin in 4 non-neoplastic brain tissues and 29 glioma tissues
(January – November, 2011).
Feature Variable No. (%) Methylated no. (%) Unmethylated no. (%) Methylation Rate(%) p-value
*
Gender Female 17(51.5) 3(9.1) 14(42.4) 17.6 0.198
Male 16(48.5) 6(18.2) 10(30.3) 37.5 –
Age #60 27(81.8) 6(18.2) 21(63.6) 22.2 0.186
.60 6(18.2) 3(9.1) 3(9.1) 50.0 –
Histology NB 4(42.4) 0(0) 4(12.1) 0 0.018
{
Low-grade 10(30.3) 1(3.0) 9(27.3) 10.0 –
High-grade 19(57.6) 8(24.2) 11(33.3) 42.1 –
Total Glioma 29(87.9) 9(27.3) 20(60.6) 31.0 –
NB: non-neoplastic brains;
*: Chi-square test;
{: the compare between the sum of NB and low-grade gliomas and high-grade gliomas.
doi:10.1371/journal.pone.0038074.t005
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China).
Statistical Analysis
All immunohistochemical pictures for calculating IOD were
magnified 200 times and captured at the same pixel and the same
white balance. Four pictures were taken in the random areas per
section, which had no necrotic tissues. Positive signal IOD value
which represents the neogenin level in pictures was calculated by
the image pro-plus 6.0. SPSS18.0 was used to perform statistical
analyses. One-Way ANOVA was used in the comparison of tumor
grade, tumor size and patients’ age, while the comparison between
the groups applied the Least Significant Difference method.
Independent t-tests were used in the comparison of tumor latency,
gender, length of being in hospital and location. Kaplan-Meier
plot and Cox proportional hazards models were applied to analyse
the associations between neogenin and high-grade glioma. The
paired t-test was used in comparison of the primary and recurrent
cases. With the p-value less than 0.05, the difference was
statistically significant.
Supporting Information
Table S1 Clinicopathologic information and neogenin
expression profile in paired surrounding and glioma
tissues of 13 patients and 2 normal brains. F: female; M:
male; IOD: integral optical density; PD: pathological diagnosis;
NB: normal brain tissue, NB1 is the normal tissue from a cerebral
hemorrhage, NB2 is the tonsilla cerebelli from a Arnold-Chiari
malformation patient; PA: pilocytic astrocytoma; LGA: diffuse
astrocytoma; ODG: oligodendroglioma; MOA: oligoastrocytoma;
AO: anaplastic oligodendroglioma; AA: anaplastic astrocytoma;
AMOA: anaplastic mixed oligoastrocytoma; GBM: glioblastoma.
The ratio is the value of neogenin divided by b-actin.
(PDF)
Table S2 Clinicopathologic information and neogenin
expression profile of 69 patients with primary glioma. F:
female; M: male; Sub: subtentorial; Sup: supratentorial; d: day; m:
month; y: year; (o) represents the diameter recorded by visual
inspection; IOD: integral optical density; PD: pathological
diagnosis; PA: pilocytic astrocytoma; LGA: diffuse astrocytoma;
ODG: oligodendroglioma; MOA: oligoastrocytoma; AO: anaplas-
tic oligodendroglioma; AA: anaplastic astrocytoma.
(PDF)
Table S3 Clinicopathologic information and neogenin
expression profile of 16 primary and recurrent glioma
patients. F: female; M: male; IOD: integral optical density; PD:
pathological diagnosis; LGA: diffuse astrocytoma; MOA: oligoas-
trocytoma; AO: anaplastic oligodendroglioma; AA: anaplastic
astrocytoma; GBM: glioblastoma.
(PDF)
Figure 7. Overexpression of neogenin in SHG-44 cell line. (A) Western blot results showed neogenin expression in the blank control which
was untreated (Con), the negative control which was transfected by empty vector (Vec) and the over-expressive group which was transfected by
neogenin expression plasmid (Neo) in SHG-44 cell line at 48 hours after transfection; (B-D) Status of cells in the blank, negative and over-expressive
group of neogenin respectively at 48 h after transfection. (E) Apoptotic distribution maps of cells in the blank, negative and over-expressive group
were drew by flow cytometry assay respectively. (F) Average apoptotic rate of cells in the blanck, negative and over-expressive group in the flow
cytometry assay, One-Way ANOVA, n=3, **p,0.01, error bars indicate standard error means.
doi:10.1371/journal.pone.0038074.g007
Correlation between Neogenin and Glioma
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e38074Table S4 Clinicopathologic information of patients
consisting of 29 gliomas and 4 non-neoplastic brain
tissues who were checked by MSP. MSP: methylation-
specific polymerase chain reaction; NB: non-neoplastic brain
tissues, NB1 is the normal tissue from a meningioma patient, NB2
is the normal tissue of a cerebral hemorrhage patient, NB3 and
NB4 are the surrounding tissues of glioma; EO: ependymoma; PD:
pathological diagnosis; PA: pilocytic astrocytoma; LGA: diffuse
astrocytoma; ODG: oligodendroglioma; MOA: oligoastrocytoma;
AO: anaplastic oligodendroglioma; GBM: glioblastoma; +:
positive; 2: negative.
(PDF)
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